BIVI - ATTENTION NASDAQ: BIVI INVESTORS: Contact Berger Montague About a BioVie Inc. Class Action Lawsuit | Benzinga
PHILADELPHIA, Feb. 03, 2024 (GLOBE NEWSWIRE) -- Berger Montague advises investors that a securities fraud class action lawsuit has been filed against BioVie Inc. ("BioVie" or the "Company") (NASDAQ:BIVI) on behalf of purchasers of BioVie's securities between August 5, 2021 and November 29, 2023, inclusive (the "Class Period").
Investor Deadline: Investors who purchased or acquired BioVie securities during the Class Period may, no later than March 19, 2024, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation, please contact Berger Montague: James Maro at jmaro@bm.net or (267) 637-3176, or Andrew Abramowitz at aabramowitz@bm.net or (215) 875-3015 or CLICK HERE.
BioVie is a clinical stage biopharmaceutical company headquartered in Carson City, NV. During the Class Period, BioVie conducted a Phase 3 clinical trial of NE3107, a drug being developed for the treatment of Alzheimer's Disease.
On November 29, 2023, BioVie issued a press release accompanying an investor presentation disclosing top line data from its clinical trial of NE3107 for the treatment of mild to moderate Alzheimer's Disease. The press release stated that the trial started during the ...